Kids' Cancer Drugs Struggle

This is a news story, published by USA Today, that relates primarily to Yadav news.

Yadav news

For more Yadav news, you can click here:

more Yadav news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

USA Today news

For more news from USA Today, you can click here:

more news from USA Today

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

pediatric cancer drugs

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Several pediatric cancer drugs news, pediatric oncology drugs news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

pediatric cancer drug

USA Today

•

Kids with cancer fight for their lives, but the drugs they need are hard to find

Summary

Nutrition label

79% Informative

Several pediatric cancer drugs are in shortage and others have been discontinued, the FDA says.

Experts say shortages have existed for decades and have been growing for decades .

Advocacy groups have tried to get manufacturers, wholesalers and hospitals on the same page.

It can take months for a pharmaceutical company to resolve a quality issue and resume production, expert says.

The best way to address the root causes of the cancer drug shortage is to make these medications more profitable, experts say.

This could mean bumping up the price of these generics in what Yadav calls a “market resiliency premium” The federal government could also create incentives for new drugmakers.

VR Score

Informative language

Neutral language

Article tone

informal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful